Document is current

Article History

Received: 10 October 2025

Accepted: 16 July 2026

First Online: 31 July 2026

Declarations

Competing interests: FH declares no competing interests. T(akumi)K has received honoraria from Daiichi Sankyo outside the submitted work. MO has received honoraria from, or collaborated as a researcher with, Pfizer Japan, Chugai Pharmaceutical, Daiichi Sankyo, and SUSMED, outside the submitted work. TF declares no competing interests. RI declares no competing interests. AI declares no competing interests. KM declares no competing interests. T(oshiaki)K has received speakers’ honoraria from, or a consultant to, Lundbeck Japan, Otsuka, Takeda Pharmaceutical, Viatris, outside the submitted work. AY declares no competing interests. SK has received speaker’s honoraria from Eisai Co., Ltd., Inter Reha Co., Ltd., Kowa Company, Ltd., Lundbeck Japan K.K., Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and Viatris Inc.; consulting fees from Kyowa Pharmaceutical Industry Co., Ltd., Teijin Pharma Ltd., and Inter Reha Co., Ltd.; and research grants from Teijin Pharma Ltd. HK has received honoraria and research support from emol Inc.; honoraria from Welbe Inc., Lundbeck Japan K.K., Shionogi & Co., Ltd., and Viatris Inc.; consulting fees from MICIN Inc.; and honoraria from PwC Consulting LLC, all outside the submitted work. HO declares no competing interests. KW received grants from Eisai, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Otsuka Pharmaceutical, Sumitomo Pharma, Takeda Pharmaceutical, speaker’s honoraria from Astra Zeneca, Boehringer Ingelheim, Eisai, Janssen Pharmaceutical, Kyowa Pharmaceutical, Lundbeck Japan, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Ono Pharmaceutical, Otsuka Pharmaceutical, Shionogi, Sumitomo Pharma, Takeda Pharmaceutical, Teijin Pharma, Viatris, and consulting fees from Boehringer Ingelheim, Daiichi Sankyo, Eisai, Janssen Pharmaceutical, Kyowa Pharmaceutical, Lundbeck Japan, Luye Pharma, Mitsubishi Tanabe Pharma, Nippon Chemiphar, Ono Pharmaceutical, Otsuka Pharmaceutical, Sumitomo Pharma, Takeda Pharmaceutical, and Viatris. NO has received research support or speakers’ honoraria from, or has served as a joint researcher with, or a consultant to, Sumitomo Pharma, Otsuka, Viatris, Eisai, Mochida, Kyowa Pharmaceutical Industry, Nihon Medi-Physics, Nippon Chemiphar, Medical Review, Nippon Boehringer Ingelheim, SUSMED, outside the submitted work. TN has received research support or speakers’ honoraria from, or has served as a joint researcher with, or a consultant to, Sumitomo Pharma, Otsuka, Viatris, Eisai, Mochida and Janssen outside the submitted work. KT declares no competing interests. KN received grants paid to his institution from Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical Co.; payment/honoraria from Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical Co.